Ju Won-Kyu, Perkins Guy A, Kim Keun-Young, Bastola Tonking, Choi Woo-Young, Choi Soo-Ho
Hamilton Glaucoma Center and Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, CA, 92093, USA.
National Center for Microscopy and Imaging Research, Department of Neurosciences, University of California San Diego, La Jolla, CA, 92093, USA.
Prog Retin Eye Res. 2023 Jul;95:101136. doi: 10.1016/j.preteyeres.2022.101136. Epub 2022 Nov 16.
Glaucoma is a leading cause of irreversible blindness worldwide and is characterized by a slow, progressive, and multifactorial degeneration of retinal ganglion cells (RGCs) and their axons, resulting in vision loss. Despite its high prevalence in individuals 60 years of age and older, the causing factors contributing to glaucoma progression are currently not well characterized. Intraocular pressure (IOP) is the only proven treatable risk factor. However, lowering IOP is insufficient for preventing disease progression. One of the significant interests in glaucoma pathogenesis is understanding the structural and functional impairment of mitochondria in RGCs and their axons and synapses. Glaucomatous risk factors such as IOP elevation, aging, genetic variation, neuroinflammation, neurotrophic factor deprivation, and vascular dysregulation, are potential inducers for mitochondrial dysfunction in glaucoma. Because oxidative phosphorylation stress-mediated mitochondrial dysfunction is associated with structural and functional impairment of mitochondria in glaucomatous RGCs, understanding the underlying mechanisms and relationship between structural and functional alterations in mitochondria would be beneficial to developing mitochondria-related neuroprotection in RGCs and their axons and synapses against glaucomatous neurodegeneration. Here, we review the current studies focusing on mitochondrial dynamics-based structural and functional alterations in the mitochondria of glaucomatous RGCs and therapeutic strategies to protect RGCs against glaucomatous neurodegeneration.
青光眼是全球不可逆性失明的主要原因,其特征是视网膜神经节细胞(RGCs)及其轴突进行性、多因素缓慢退变,导致视力丧失。尽管青光眼在60岁及以上人群中患病率很高,但目前导致青光眼进展的因素尚未完全明确。眼压(IOP)是唯一已证实可治疗的危险因素。然而,降低眼压不足以预防疾病进展。青光眼发病机制的一个重要研究方向是了解RGCs及其轴突和突触中线粒体的结构和功能损伤。青光眼的危险因素,如眼压升高、衰老、基因变异、神经炎症、神经营养因子缺乏和血管调节异常,都是青光眼线粒体功能障碍的潜在诱因。由于氧化磷酸化应激介导的线粒体功能障碍与青光眼性RGCs线粒体的结构和功能损伤有关,了解线粒体结构和功能改变的潜在机制及其关系,将有助于开发针对RGCs及其轴突和突触的线粒体相关神经保护措施,以对抗青光眼性神经退变。在此,我们综述了目前聚焦于青光眼性RGCs线粒体基于线粒体动力学的结构和功能改变的研究,以及保护RGCs免受青光眼性神经退变的治疗策略。